Malignant peripheral nerve sheath tumors (MPNSTs) are rare and aggressive soft tissue sarcomas with a significant susceptibility to metastasize early in their course.
| INTRODUCTION
Malignant peripheral nerve sheath tumor (MPNST) is a rare malignant neoplasm, which corresponds to 2%-10% of all soft tissue sarcomas. [1] [2] [3] These tumors mainly affect adults with a median age of 35-44 years and rarely affect children. 2, [4] [5] [6] These are aggressive tumors with a significant susceptibility to metastasize early in their course. [4] [5] [6] MPNSTs have a widely recognized association with neurofibromatosis type 1 (NF1) in approximately 50% of all cases.
2,4-8 Such association is of note since MPNST is the main cause of death in such patients. 9 Surgery is still the mainstay of treatment and the only chance of cure. Extensive tumor resection is the main goal, although not always possible due to the difficult management of tumors in challenging locations, which causes frequent local recurrence and consequently the occurrence of distant metastases. 6 Generally, the 5-year overall survival (OS) is about 44%. 8 MPNSTs have a complex karyotype, showing great genetic variability with expression of multiple oncogenes and loss of tumor suppressor genes. [10] [11] [12] [13] This usually accounts for the failure of the chemotherapeutic regimens and limits the findings of potentially new molecular therapeutic targets. [14] [15] [16] The study of tumor microenvironment in MPNSTs emerges in this context, since it has an important role for several other neoplasms. Some therapeutic approaches directed to non-neoplastic cells are currently available demonstrating promising results in advanced melanomas by blocking T-cell regulatory function (ipilimumab and nivolumab), 17, 18 in renal cell carcinomas by blocking angiogenesis, 19 and in solid tumors by preventing bone events related to bone metastasis (denosumab). 20 Recently, there has been an increasing interest in the role of mast cells in the tumor microenvironment and its potential use as a target for cancer therapies. 19, [21] [22] [23] [24] [25] [26] [27] [28] Mast cells assist in the coordination of a local inflammatory response that ultimately leads to remodeling of the extracellular matrix, to immune response modulation, and also to tumor-induced neoangiogenesis. They infiltrate tumor microenvironment stimulated by the stem cell factor (SCF), which is secreted by both tissue and neoplastic cells. [29] [30] [31] [32] Mast cells can promote or protect against tumor onset and progression, which can be defined by the specific interaction with local microenvironment. 26 For pulmonary adenocarcinomas, 25 mast cell accumulation coupled with angiogenesis contributes to tumor progression and reduced survival. Conversely, the occurrence of stromal mast cells in breast carcinoma was associated to a better survival. 27 For renal cell carcinomas, the prognostic significance of mast cell density (MCD) and angiogenesis is still controversial. The involvement of mast cells in the pathogenesis and progression of diffuse and encapsulated neurofibromas in patients affected by NF1 was suggested by Tucker et al. 34 MCD was positively correlated to tumor overall vascularity, even though blood vessels were evenly distributed throughout tumors. 34 Friedrich et al 35 have shown that, compared to NF1-associated and sporadic neurofibromas, MPNST has increased microvascular density (MVD) with decreased mast cell infiltration. The role of mast cell infiltration in MPNSTs was largely unknown until recently, when Dodd et al 36 demonstrated an accelerated tumor onset in experimental models and human tissues with elevated levels of hematopoietic cells. 36 The clinical significance of the interaction mast cell/ MPNST tumor microenvironment is yet to be determined, however. In this study, we investigate MCD, MVD, and Ki-67 labeling index (LI) in MPNST. A secondary aim was to correlate histological staining to clinical data and survival in patients with and without NF1. Herein, we show for the first time that MCD is not related to MVD due to different distribution. On the other hand, higher MVD distinguish a subpopulation of MPNST who carry a significant worse prognosis.
| METHODS

| Patients and tumors
Between January 1990 and December 2010, 92 consecutive patients were admitted at the National Cancer Institute (INCA, Rio de Janeiro, Brazil) with the diagnosis of MPNST. The epidemiological, clinical, and therapeutic characteristics were previously published. 37 The histological diagnosis was confirmed by experienced institutional pathologists and reviewed for this study (TMV, WSN). Tumors were considered NF1-associated if the patient had the clinical diagnosis of NF1, based on two or more of the National Institutes of Health criteria. 38 The exclusion criteria were as follows:
patients who underwent incisional biopsy or neoadjuvant 
| Histological evaluation and immunohistochemical staining
Formalin-fixed and paraffin-embedded tissues were retrieved from our archives and analyzed for the histopathological grade (whether high-or low-grade) and the occurrence of heterologous differentiation. Then, tissues were processed routinely and two samples were chosen: one representative of the tumor core and one representative of the tumor periphery (up to 5 mm to the tumor margin). From these, tissues were cut into 0.5 μm slices, fixed on slides, and stained with hematoxylin-eosin. Sections of 3 μm were used for immunohistochemical reactions according to standard techniques. The polyclonal rabbit antibody to CD117 identified all activated mast cells (Dako, Santa Clara, CA; c-Kit clone, dilution 1:1000), the monoclonal mouse antibody to CD31 was used as a marker for endothelial cells (Dako; JC70A clone, dilution 1:800), and the mouse monoclonal antibody against Ki-67 was used as a marker for LI (Dako; MIB-1 clone, dilution 1:700). Positive controls for immunohistochemical reactions were done.
| Image acquisition and digital image analysis
All immunostained tissue sections were scanned and analyzed by using an Aperio ScanScope X Slide Scanner (Aperio Technologies, Vista, CA) with a 20-fold magnification (0.5 mμ resolution). According to manufacturer's manual, the computer-based algorithm performed quantification automatically and results were given as a percentage of labeled cells (%) for mast cells and LI count. Digital imaging analysis was performed in all histological sections and presented as an average of the whole tumor specimen, considering the tumor core and the periphery separately. CD117 stained specimens were analyzed for MCD, while CD31 was applied to quantify MVD. It is worth noting that only vessels with a defined lumen were considered, the remaining ones were manually excluded from the measurement. MVD results were expressed as the number of vessels per square millimicron (vessels/mμ 2 ). 
| Statistical analysis
| RESULTS
Out of the 92 patients admitted, 69 patients underwent surgery and 23 were transferred for palliative care. Other 40 patients were excluded due to neoadjuvant RT (n = 19) and incomplete histopathological records (n = 21). The excluded patients had a mean age of 42.41 ± 22.63 years (range 2-84 years), 55.5% had NF1, and 54.5% were affected by large tumors (>10 cm). Twenty-nine patients (34 tumors) fulfilled our criteria and comprised our study population. Seventeen patients were male (58.6%), and patients affected by NF1 were generally younger than those having sporadic tumors (40.83 ± 10.53 and 50.24 ± 16.42 years, respectively). Twelve patients (41%) had 17 NF1-associated MPNSTs (two patients had two tumors; one patient had four tumors). The remaining 17 tumors were sporadic. All tumors were high-grade MPNSTs and none presented heterologous differentiation. We had no patient with RT-induced MPNSTs. Demographic and clinical characteristics of the participants are presented in Table  1 . Groups were fairly similar according to clinical characteristics, except death, which was marginally significant (NF1-associated MPNSTs [100%], sporadic MPNST [71%]; P = 0.058).
| MCD and distribution within MPNSTs
The prevalence of mast cells was evenly distributed throughout tumor core and periphery. There was no clustering of mast cells around specific structures within the tumor. The mean MCD for the whole group was 2.19 ± 2.03% (range, 0. 19-8.96 ) in the tumor core and 2.67 ± 3.62% (range, 0.27-15.27) in the periphery of MPNSTs. Density and distribution of mast cells were similar between NF1-associated and sporadic MPNSTs (Table 2; Figure 1 ).
| MVD and distribution within MPNSTs
Regarding MVD, the number of vessels was higher in the periphery, but did not reach statistical significance when evaluated the entire population (197.6 ± 58.39 and 175.6 ± 62.97 vessels/ mμ 2 , respectively). Subgroup analyses demonstrated that the number of vessels was clearly higher in the periphery of sporadic tumors in comparison to the tumor core (mean of 180 vessels/ mμ 2 and mean of 152 vessels/mμ 2 , respectively) (P = 0.037). MVD was similarly distributed throughout periphery (P = 0.14) and core (P = 0.053) of NF1-associated MPNSTs and sporadic tumors (Table 2; Figure 1 ).
| Proliferative Index and distribution in MPNSTs
The mean overall Ki-67 LI was 7.65 ± 11.96% in the tumor core and 5.87 ± 8.33% in the periphery. LI showed similar levels in the core and periphery of NF1-associated MPNSTs and sporadic tumors (Table 2; Figure 1 ).
| Correlation with clinical characteristics and survival
Even though we found higher MVD at the periphery of sporadic MPNSTs, there was no correlation between MVD, MCD, LI, tumor distribution, or NF1 status (Table 3) . When analyzed by tumor size, tumors greater than 10 cm had higher MVD both in the tumor core and periphery, but not in a significant level.
Median OS was 28 months for combined NF1-associated/sporadic MPNSTs. In the univariate analysis, patients with NF1 had a significant reduction in the OS from 57 to 14 months (hazard ratio [HR] 2.44 [95% CI 1.06-5.6, P = 0.036]), when compared to sporadic tumors. Increasing tumor was also associated with a worse outcome in the way that tumors greater than 10 cm had an OS of 16 (Table 4) . Conversely, Ki-67 LI has shown no correlation to outcome. Survival analyses for NF1, tumor size, and MVD (tumor periphery) are shown in Figure 2 . 
| DISCUSSION
Our study provides evidence about MPNST microenvironment as it shows a relatively similar distribution of MCD, Ki-67 LI, and MVD throughout the tumor in whole tissue sections. Sporadic MPNSTs comprised the only exception because of the marked neovascularization in the periphery. Correlation studies with clinical variables confirmed that NF1 status, tumor size (>10 cm), and MVD in tumor periphery (higher tercile) lead to a significant reduction of the OS. In the multivariate analysis, only higher MVD in tumor periphery retained an independent prognostic significance in the studied population.
Since the 1990 s, mast cells were shown to play a role in the formation of neurofibromas, when distinct groups of researchers found a much higher distribution in NF1-associated and sporadic tumors compared to adjacent areas of normal skin. 40, 41 Contemporary studies have contributed to this issue by demonstrating the essential participation of mast cells in the pathogenesis of plexiform neurofibromas in both animal models 33 and humans. 34 In this context, neurofibromin-deficient Schwann cells (Nf1 −/−) secrete chemotactic factors (Kit ligand) to stimulate the migration of haploinsufficient mast cells (Nf1 +/−), which in turn can locally secrete neural growth factor (NGF) and vascular endothelial growth factor (VEGF) in the tumor microenvironment. 33 Recently, Dodd et al 36 confirmed in experimental models and human tissues that elevated levels of mast cells developed NF1-associated MPNSTs at an accelerated rate. Quantification was done with toluidine blue staining (sum of six fields for a single slide) for mice models and c-Kit immunohistochemistry for human tissues (<5, 5-50, and >50 mast cells). Importantly, NF1-associated tumors had significantly more mast cells than sporadic ones (more than 5 cells in about 50% and 30%, respectively). 36 Although it
is not possible to directly compare these studies because of different counting and immunolabeling methods, our results corroborate the low MCD in MPNSTs, as demonstrated by Friedrich et al, 35 indicating that mast cells are potentially less relevant in the progression of malignant tumors. In addition, our work also shows that MCD lacks prognostic value. Generally speaking, c-kit expression is the most commonly used staining technique to study the role of mast cells in peripheral nerve sheath tumors, [34] [35] [36] certainly because c-kit driven mast cell activation promotes the release of tryptase, the most important pro-angiogenic factor. 42, 43 Canine models confirmed such assumption by demonstrating the correlation of c-kit expression to the degranulated status on mast cells. 43 For breast cancer, mast cell staining for c-kit and tryptase are essentially the same due to an almost perfect correlation suggesting that c-kit expression represents tryptase activation. Such observation has a potential therapeutic role in the way that it could characterize a novel anti-angiogenic target for either c-kit receptor or tryptase inhibitors in patients having elevated c-kit expression. 42 Similar to MCD, Ki-67 LI shows a relatively similar distribution in tumor core and periphery regardless of the NF1 status. In addition, it has no correlation with the outcome. Our findings are not in line with those presented by Watanabe et al, 44 in which tumors with LI greater than 25% have a worse prognosis. It is worth mentioning that only two patients in our study showed LI greater than 25%, nonetheless without impact in the OS. 
| Limitations
Our study has some key limitations. First, we have conducted a retrospective single-center cohort analysis. In that way, data collection and characterization of patients are prone to inaccuracies and inconsistencies over the course of the study. Second, about two-thirds of the patients were excluded from our evaluation because of advanced disease, neoadjuvant RT, and unavailable histopathological data. This could raise a question of whether our results are representative of the entire population. Considering similar epidemiological characteristics, age and NF1 status between the studied and the excluded population, we believe our findings are representative. It should be noted, however, that this is a rare disease, and we present herein the largest study on the investigation of neovascularization and mast cell distribution for MPNSTs.
| CONCLUSIONS
Diverse mast cell and microvascular distribution suggest that angiogenesis in MPNST occurs independently and mast cells are potentially not involved in tumor progression. Besides, MCD lacks prognostic value. NF1 status and increasing tumor size remain the most important predictors of OS in MPNSTs in our population. Higher MVD was correlated to tumor size and has prognostic significance with possible therapeutic implications.
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